Targeting anticancer immunity in melanoma tumor microenvironment: Unleashing the potential of adjuvants, drugs, and phytochemicals

Journal of drug targeting, Journal Year: 2024, Volume and Issue: 32(9), P. 1052 - 1072

Published: July 23, 2024

Melanoma poses a challenge in oncology because of its aggressive nature and limited treatment modalities. The tumour microenvironment (TME) melanoma contains unique properties such as an immunosuppressive high-density environment, unusual vasculature, high number stromal cells. In recent years, numerous experiments have focused on boosting the immune system to effectively remove malignant Adjuvants, consisting phytochemicals, toll-like receptor (TLR) agonists, cytokines, shown encouraging results triggering antitumor immunity augmenting therapeutic effectiveness anticancer therapy. These adjuvants can stimulate maturation dendritic cells (DCs) infiltration cytotoxic CD8+ T lymphocytes (CTLs). Furthermore, nanocarriers help deliver immunomodulators antigens directly stroma, thereby improving their efficacy against remodelling TME utilising other be combined with current modalities for therapy outcomes. This review article explores potential adjuvants, drugs, nanoformulations enhancing potency macrophages, CTLs, natural killer (NK) Additionally, capacity these agents repress function components TME, subsets myeloid will discussed.

Language: Английский

Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive Review

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(18), P. 5409 - 5409

Published: Sept. 12, 2024

Over the past several decades, advancements in treatment of

Language: Английский